All > Paid Studies Montana > New Jersey

Niraparib for Stage IVA Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Stage IVA Prostate Cancer+6 MoreNiraparib - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial is studying niraparib as a possible treatment for prostate cancer. It is testing how well it works with standard treatments of radiation and hormonal therapy, and what the side effects are.

Eligible Conditions
  • Stage IVA Prostate Cancer
  • Prostate Adenocarcinoma
  • Stage III Prostate Cancer
  • Stage II Prostate Cancer
  • Stage IIIA Prostate Cancer
  • Stage IIIB Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
External Beam Radiation Therapy
1
Niraparib
1
TRPV6 Calcium Channel Inhibitor SOR-C13

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Up to 3 years

At 24 months
Pathologic Complete Response (pCR)
Year 3
Overall Survival
Year 3
Prostate cancer-specific survival
Year 3
Time to distant metastases
Year 2
Maintenance of disease-free state
Up to 3 years
Biochemical Progression-Free Survival
Exome sequencing of deoxyribonucleic acid (DNA) repair genes and detected alterations
Incidence of Adverse Events (Phase II)
Single nucleotide polymorphisms
Time to local/regional or distant progression
Transcription-wide analysis of gene expression

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
External Beam Radiation Therapy
1
Niraparib
1
TRPV6 Calcium Channel Inhibitor SOR-C13

Side Effects for

Stage 1 (Cohort 2): Niraparib + Pembrolizumab
57%Nausea
52%Decreased appetite
48%Anaemia
48%Constipation
43%Fatigue
38%Dyspnoea
24%Oedema peripheral
24%Vomiting
24%Stomatitis
24%Platelet count decreased
19%Insomnia
19%Blood alkaline phosphatase increased
19%Arthralgia
19%Pruritus
14%Pneumonia
14%Diarrhoea
14%Cough
14%Pain
14%Chills
14%Upper respiratory tract infection
14%Weight decreased
14%Neutrophil count decreased
14%Dysgeusia
14%Back pain
14%Muscular weakness
10%Depression
10%Erythema
10%Vision blurred
10%Pleural effusion
10%Atrial fibrillation
10%Neuropathy peripheral
10%Haemorrhoids
10%Haemorrhoidal haemorrhage
10%Anxiety
10%Proctalgia
10%Oropharyngeal pain
10%Wheezing
10%Non-cardiac chest pain
10%Productive cough
10%Gait disturbance
10%Chest pain
10%Urinary tract infection
10%Hypophosphataemia
10%Aspartate aminotransferase increased
10%Dehydration
10%Blood creatinine increased
10%Hypokalaemia
10%Lymphocyte count decreased
10%Alanine aminotransferase increased
10%Rash maculo-papular
10%Pain of skin
10%Overdose
10%Hypothyroidism
5%Angina pectoris
5%Dizziness
5%Sepsis
5%Dysphonia
5%Sinus tachycardia
5%Neuroendocrine carcinoma of the skin
5%Gastrooesophageal reflux disease
5%Candida infection
5%Fall
5%Pulmonary embolism
5%Pneumonitis
5%Respiratory failure
5%Cardiac arrest
5%Pericardial effusion
5%Intestinal obstruction
5%Lactic acidosis
5%Diverticulitis
5%Lethargy
5%Headache
5%Cancer pain
5%Toxicity to various agents
5%Abdominal pain
5%Haematochezia
5%Nasal congestion
5%Asthenia
5%Pyrexia
5%Malaise
5%Hypomagnesaemia
5%Hyponatraemia
5%Amylase increased
5%Hepatic enzyme increased
5%Peripheral sensory neuropathy
5%Pain in extremity
5%Hyperhidrosis
5%Tachycardia
5%Contusion
5%Hypotension
5%Lipase increased
5%Syncope
5%Hyperglycaemia
This histogram enumerates side effects from a completed 2021 Phase 2 trial (NCT03308942) in the Stage 1 (Cohort 2): Niraparib + Pembrolizumab ARM group. Side effects include: Nausea with 57%, Decreased appetite with 52%, Anaemia with 48%, Constipation with 48%, Fatigue with 43%.

Trial Design

3 Treatment Groups

Phase II, Arm I (GnRH, IMRT)
1 of 3
Phase II, Arm II (niraparib, GnRH, IMRT)
1 of 3
Phase I (niraparib, GnRH, IMRT)
1 of 3

Active Control

Experimental Treatment

180 Total Participants · 3 Treatment Groups

Primary Treatment: Niraparib · No Placebo Group · Phase 2

Phase II, Arm II (niraparib, GnRH, IMRT)Experimental Group · 3 Interventions: Gonadotrophin Releasing Hormone, Niraparib, Intensity-Modulated Radiation Therapy · Intervention Types: Biological, Drug, Radiation
Phase I (niraparib, GnRH, IMRT)Experimental Group · 3 Interventions: Gonadotrophin Releasing Hormone, Niraparib, Intensity-Modulated Radiation Therapy · Intervention Types: Biological, Drug, Radiation
Phase II, Arm I (GnRH, IMRT)ActiveComparator Group · 2 Interventions: Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy · Intervention Types: Biological, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niraparib
FDA approved
Intensity-Modulated Radiation Therapy
2010
Completed Phase 3
~1660

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

NRG OncologyLead Sponsor
219 Previous Clinical Trials
95,344 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,099 Previous Clinical Trials
41,145,607 Total Patients Enrolled
2 Trials studying Stage IVA Prostate Cancer
400 Patients Enrolled for Stage IVA Prostate Cancer
M. D MichaelsonPrincipal InvestigatorNRG Oncology
1 Previous Clinical Trials
70 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top